![Jason Werner](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jason Werner
Operationeel Directeur bij ALIMERA SCIENCES, INC.
Vermogen: 686 250 $ op 31-05-2024
Actieve functies van Jason Werner
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
ALIMERA SCIENCES, INC. | Operationeel Directeur | 02-10-2023 | - |
Directeur/Bestuurslid | 17-05-2023 | 02-10-2023 | |
InflammX Therapeutics, Inc.
![]() InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | Directeur/Bestuurslid | - | - |
Loopbaan van Jason Werner
Eerdere bekende functies van Jason Werner
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
SightStream Biotherapeutics
![]() SightStream Biotherapeutics BiotechnologyHealth Technology SightStream Biotherapeutics develops cytoprotectives to reverse ocular cell death. The company is based in Dallas-Fort Worth, TX. The company was founded by Jack Jiagang Zhao. | Algemeen Directeur | 01-05-2021 | 30-09-2023 |
Eyevance Pharmaceuticals LLC
![]() Eyevance Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Eyevance Pharmaceuticals LLC operates as a pharmaceutical company. It develops and commercializes ophthalmic products that enable optimal vision for the patients. The company was founded by Jerry St. Peter and Jason Werner in September 2017 and is headquartered in Forth Worth, TX. | Operationeel Directeur | 01-09-2017 | 01-09-2020 |
Oprichter | 01-09-2017 | 01-09-2020 | |
Eyevance Pharmaceuticals Holdings, Inc.
![]() Eyevance Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Eyevance Pharmaceuticals Holdings, Inc operates as a holding company through its subsidiaries develops ophthalmic therapies for the ocular surface and anterior segment. The company was founded by Jerry St. Peter and Jason Werner in September 2017 and is headquartered in Fort Worth, TX. | Operationeel Directeur | 01-09-2017 | 01-09-2020 |
Opleiding van Jason Werner
University of New Hampshire | Undergraduate Degree |
Statistieken
Internationaal
Verenigde Staten | 7 |
Operationeel
Chief Operating Officer | 3 |
Director/Board Member | 2 |
Founder | 1 |
Sectoraal
Health Technology | 5 |
Consumer Services | 2 |
Commercial Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
ALIMERA SCIENCES, INC. | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
Eyevance Pharmaceuticals LLC
![]() Eyevance Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Eyevance Pharmaceuticals LLC operates as a pharmaceutical company. It develops and commercializes ophthalmic products that enable optimal vision for the patients. The company was founded by Jerry St. Peter and Jason Werner in September 2017 and is headquartered in Forth Worth, TX. | Health Technology |
Eyevance Pharmaceuticals Holdings, Inc.
![]() Eyevance Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Eyevance Pharmaceuticals Holdings, Inc operates as a holding company through its subsidiaries develops ophthalmic therapies for the ocular surface and anterior segment. The company was founded by Jerry St. Peter and Jason Werner in September 2017 and is headquartered in Fort Worth, TX. | Health Technology |
InflammX Therapeutics, Inc.
![]() InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | Commercial Services |
SightStream Biotherapeutics
![]() SightStream Biotherapeutics BiotechnologyHealth Technology SightStream Biotherapeutics develops cytoprotectives to reverse ocular cell death. The company is based in Dallas-Fort Worth, TX. The company was founded by Jack Jiagang Zhao. | Health Technology |
- Beurs
- Insiders
- Jason Werner
- Ervaring